270 related articles for article (PubMed ID: 30912402)
21. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
[TBL] [Abstract][Full Text] [Related]
22. Promoter CpG island hypermethylation during breast cancer progression.
Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of DAPK1 hypermethylation in gliomas: A site-specific analysis.
Li X; Pu J; Liu J; Chen Y; Li Y; Hou P; Shi B; Yang Q
Pathol Res Pract; 2018 Jul; 214(7):940-948. PubMed ID: 29807777
[TBL] [Abstract][Full Text] [Related]
24. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
25. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
26. Analysis of FHIT gene methylation in egyptian breast cancer women: association with clinicopathological features.
Zaki SM; Abdel-Azeez HA; El Nagar MR; Metwally KA; S Ahmed MM
Asian Pac J Cancer Prev; 2015; 16(3):1235-9. PubMed ID: 25735361
[TBL] [Abstract][Full Text] [Related]
27. Association of aberrant DNA methylation with clinicopathological features in breast cancer.
Tserga A; Michalopoulos NV; Levidou G; Korkolopoulou P; Zografos G; Patsouris E; Saetta AA
Oncol Rep; 2012 May; 27(5):1630-8. PubMed ID: 22159596
[TBL] [Abstract][Full Text] [Related]
28. Hypermethylation of Death-Associated Protein Kinase (DAPK1) and its association with oral carcinogenesis - An experimental and meta-analysis study.
Jayaprakash C; Varghese VK; Bellampalli R; Radhakrishnan R; Ray S; Kabekkodu SP; Satyamoorthy K
Arch Oral Biol; 2017 Aug; 80():117-129. PubMed ID: 28412611
[TBL] [Abstract][Full Text] [Related]
29. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
[TBL] [Abstract][Full Text] [Related]
30. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
Moelans CB; Verschuur-Maes AH; van Diest PJ
J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
[TBL] [Abstract][Full Text] [Related]
31. [Study of the CpG methylation status of ER alpha gene in estrogen receptor alpha-negative breast cancer cell lines and the role of hydralazine demethylation].
Tang B; Jiang J
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):283-7. PubMed ID: 16181550
[TBL] [Abstract][Full Text] [Related]
32. Altered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer.
Liu J; Zhang X; Liu A; Zhang D; Su Y; Liu Y; You D; Yuan L; Kong X; Wang X; Sun P
Oncotarget; 2016 Jun; 7(24):36755-36766. PubMed ID: 27191984
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of promoter hypermethylation of ERβ and RARβ2 in tumor and serum DNA in Indian breast cancer patients.
Mirza S; Sharma G; Parshad R; Srivastava A; Gupta SD; Ralhan R
Ann Surg Oncol; 2012 Sep; 19(9):3107-15. PubMed ID: 22451234
[TBL] [Abstract][Full Text] [Related]
34. Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran.
Yari K; Payandeh M; Rahimi Z
Tumour Biol; 2016 Jun; 37(6):8145-52. PubMed ID: 26715274
[TBL] [Abstract][Full Text] [Related]
35. Identification of methylation markers for the prediction of nodal metastasis in oral and oropharyngeal squamous cell carcinoma.
Melchers LJ; Clausen MJ; Mastik MF; Slagter-Menkema L; van der Wal JE; Wisman GB; Roodenburg JL; Schuuring E
Epigenetics; 2015; 10(9):850-60. PubMed ID: 26213212
[TBL] [Abstract][Full Text] [Related]
36. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
Feng W; Shen L; Wen S; Rosen DG; Jelinek J; Hu X; Huan S; Huang M; Liu J; Sahin AA; Hunt KK; Bast RC; Shen Y; Issa JP; Yu Y
Breast Cancer Res; 2007; 9(4):R57. PubMed ID: 17764565
[TBL] [Abstract][Full Text] [Related]
37. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
38. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Esteller M; Silva JM; Dominguez G; Bonilla F; Matias-Guiu X; Lerma E; Bussaglia E; Prat J; Harkes IC; Repasky EA; Gabrielson E; Schutte M; Baylin SB; Herman JG
J Natl Cancer Inst; 2000 Apr; 92(7):564-9. PubMed ID: 10749912
[TBL] [Abstract][Full Text] [Related]
39. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
40. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
